2015 News Releases

2016 | 2015 | 2014
DateTitle 
12/31/15Luminex Corporation To Present At J.P. Morgan Healthcare Conference
AUSTIN, Texas, Dec. 31, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference to be held January 11-14, 2016, in San Francisco, CA. The investor presentation will begin at 8:30 a.m. Pacific time (11:30 a.m. Eastern time) on Thursday, January 14, 2016.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  ... 
Printer Friendly Version
12/18/15Luminex Corporation Receives FDA Clearance for NxTAG® Respiratory Pathogen Panel
New closed-tube, scalable, 96-well solution meets clinical demand for respiratory testing AUSTIN, Texas, Dec. 18, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for its NxTAG® Respiratory Pathogen Panel that detects 20 clinically relevant viral and bacterial respiratory pathogens, including the atypical bacteria Chlamydophila pneumoniae and Mycoplasma pneumonia. The panel is the only respiratory assay that enables laboratories... 
Printer Friendly Version
11/10/15Luminex Corporation To Present At Upcoming Investment Conferences
AUSTIN, Texas, Nov. 10, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at two upcoming investment conferences: The Jefferies Autumn 2015 Global Healthcare Conference on Thursday, November 19 at 2:40pm GMT in London The 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1 at 12:30pm ET in New York City These investor presentations will be webcast live and may be accessed at Luminex Corporation's website ... 
Printer Friendly Version
11/02/15Luminex Corporation Reports 3rd Quarter 2015 Results
AUSTIN, Texas, Nov. 2, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the third quarter ended September 30, 2015.  Financial and operating highlights for the quarter include the following: Increased third quarter 2015 revenue by 7 percent to $60.6 million, over the third quarter of 2014. Increased Q3 2015 system sales by 26 percent to $9.6 million over the third quarter of 2014. Grew third quarter 2015 assay revenue by 12 percent ... 
Printer Friendly Version
10/28/15Luminex Corporation to Feature ARIES System and NxTAG Respiratory Pathogen Panel at AMP Annual Meeting
Recently cleared products will be highlighted at workshops, product demonstrations, events, and posters AUSTIN, Texas, Oct. 28, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it will be featuring the newly FDA-cleared ARIES® System and recently CE-marked NxTAG® Respiratory Pathogen Panel at the Association for Molecular Pathology (AMP) Annual Meeting occurring November 5 to 7, 2015 in Austin, Texas.    About ARIES® ARIES® is a sample to answer s... 
Printer Friendly Version
10/20/15Luminex Corporation and Bio-Techne Corporation Extend and Expand Partnership
Agreement through 2020; Expands Global Distribution of Award-winning Multiplexing Instrumentation AUSTIN, Texas and MINNEAPOLIS, Oct. 20, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) and Bio-Techne Corp (NASDAQ: TECH) today announced the signing of a new distribution and supply agreement through 2020. This agreement extends the relationship between the two companies for immunoassay development and commercialization of Bio-Techne biological content using the Luminex testing platfo... 
Printer Friendly Version
10/19/15Luminex Corporation Receives CE-IVD Mark for NxTAG® Respiratory Pathogen Panel
A new closed tube, scalable, 96-well based solution to meet clinical demand for respiratory testing AUSTIN, Texas, Oct. 19, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for its NxTAG® Respiratory Pathogen Panel.  The Panel detects 21 clinically-relevant viral and bacterial respiratory pathogens, including the atypical bacteria Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila. The NxTAG Respiratory... 
Printer Friendly Version
10/12/15Luminex Corporation Third Quarter Earnings Release Scheduled for November 2, 2015
AUSTIN, Texas, Oct. 12, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter ended September 30, 2015 on Monday, November 2, 2015. A press release announcing the results is scheduled for release after the close of trading. Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2015 on November 2, 2015, at 4:30 p.m. Eastern time.... 
Printer Friendly Version
10/07/15Luminex Corporation Receives FDA Clearance for ARIES® System and ARIES® HSV 1&2 Assay
AUSTIN, Texas, Oct. 7, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the company's ARIES® System and ARIES® HSV 1&2 Assay. ARIES® is a sample to answer system designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today's lean laboratory environment. ARIES® uses internal barcode scanning and other advanced features to minimize operator errors. Two independent modules each support from ... 
Printer Friendly Version
09/04/15Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference
AUSTIN, Texas, Sept. 4, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Morgan Stanley Global Healthcare Conference to be held September 16 - 18, 2015, at the Grand Hyatt Hotel in New York City. The investor presentation will begin at 11:40 a.m. Eastern time on Friday, September 18, 2015.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply&... 
Printer Friendly Version
08/26/15Luminex Corporation Submits 510(k) Application for the NxTAG® Respiratory Pathogen Panel
AUSTIN, Texas, Aug. 26, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted a 510(k) application to the FDA for the company's NxTAG® Respiratory Pathogen Panel. This panel is the only respiratory assay that will easily enable laboratories to simultaneously detect 21 respiratory pathogens in a single closed tube system in a format that scales to changes in throughput requirements and responds to seasonal changes in demand. "With the FDA submission ... 
Printer Friendly Version
08/05/15Luminex Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference
AUSTIN, Texas, Aug. 5, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 2015 Wedbush PacGrow Healthcare Conference to be held August 11 - 12, 2015, in New York City, NY. The investor presentation will begin at 4:15 p.m. Eastern time on Tuesday, August 11, 2015.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the... 
Printer Friendly Version
08/03/15Luminex Corporation Reports Record 2nd Quarter 2015 Results
AUSTIN, Texas, Aug. 3, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2015.  Financial and operating highlights for the quarter include the following: Increased second quarter 2015 revenue by 6 percent to $58.9 million, over the second quarter of 2014. Grew second quarter 2015 assay revenue by 22 percent to $24.2 million over results from the second quarter of 2014. Increased Q2 2015 royalty reven... 
Printer Friendly Version
07/14/15Luminex Corporation Submits FDA 510(k) Submissions for ARIES™ System and ARIES™ HSV 1&2 Assay
AUSTIN, Texas, July 14, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted 510(k) applications to the FDA for the company's ARIES™ System and ARIES™ HSV 1&2 Assay. The company anticipates receiving FDA clearance and CE-IVD marking before the end of the year. "The FDA submission for the ARIES platform represents the culmination of years of development work. In ARIES, we believe we have a truly differentiated product that will resonate quit... 
Printer Friendly Version
07/13/15Luminex Corporation Second Quarter Earnings Release Scheduled for August 3, 2015
AUSTIN, Texas, July 13, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter ended June 30, 2015 on Monday, August 3, 2015. A press release announcing the results is scheduled for release after the close of trading. Management will hold a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2015 on August 3, 2015, at 4:30 p.m. Eastern time. The conferen... 
Printer Friendly Version
06/08/15Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay
AUSTIN, Texas, June 8, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has commenced clinical and analytical studies to evaluate the company's ARIES™ Group B Streptococcus (GBS) Assay. "We continue to build momentum in our commercial launch schedule for the ARIES platform with the start of clinical trials for GBS, the third assay in the ARIES pipeline," said Homi Shamir, President and CEO of Luminex. "The progression of our ARIES menu with assays that are im... 
Printer Friendly Version
05/18/15Luminex Corporation To Present At Jefferies 2015 Healthcare Conference
AUSTIN, Texas, May 18, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Jefferies 2015 Global Healthcare Conference to be held June 1-4, 2015, in New York City, NY. The investor presentation will begin at 2:00 p.m. Eastern time on Wednesday, June 3, 2015.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the addre... 
Printer Friendly Version
05/04/15Luminex Corporation Reports First Quarter 2015 Results
AUSTIN, Texas, May 4, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2015. Financial and operating highlights include the following: Consolidated first quarter revenue of $57.7 million, a 2 percent increase over the first quarter of 2014. First quarter assay revenue of $25.4 million, a 17 percent increase over the first quarter of 2014. Consolidated gross profit margin was 70 percent for the first quarter o... 
Printer Friendly Version
04/27/15Luminex Corporation Provides Updates on ARIES® Clinical Trials
Clinical Trials Initiated for ARIES® Clostridium difficile Assay AUSTIN, Texas, April 27, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that testing at the clinical trial sites for the ARIES® HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway. In addition, the company has commenced clinical and analytical studie... 
Printer Friendly Version
04/13/15Luminex Corporation First Quarter Earnings Release Scheduled for May 4, 2015
AUSTIN, Texas, April 13, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter ended March 31, 2015 on Monday, May 4, 2015. A press release announcing the results is scheduled for release after the close of trading. Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2015 on May 4, 2015, at 4:30 p.m. Eastern time. The conference ... 
Printer Friendly Version
04/06/15A New Test to Simultaneously Detect 22 Respiratory Pathogens
Luminex® Corporation Launches the NxTAG™ Respiratory Pathogen Panel (RUO) - A Closed-Tube, Flexibly Scalable Solution for Respiratory Testing AUSTIN, Texas, April 6, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced the launch of the NxTAG™ Respiratory Pathogen Panel (RUO). The NxTAG Respiratory Pathogen Panel is the only respiratory assay that enables laboratories to both simultaneously detect 22 respiratory pathogens in a single closed tube system and accommodat... 
Printer Friendly Version
03/30/15Luminex Corporation Begins Clinical Trials for ARIES® System and ARIES® HSV 1&2 Assay
AUSTIN, Texas, March 30, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has commenced clinical and analytical studies to evaluate the company's ARIES® System and ARIES® HSV 1&2 Assay. Luminex plans to seek both FDA clearance and CE IVD marking this year.  "We are excited to announce the start of ARIES clinical trials as planned, which represents a key milestone in our commercial launch schedule," said Homi Shamir, President and CEO of Luminex. "Bec... 
Printer Friendly Version
03/12/15Luminex Technology Selected by Assurex Health
xTAG® Technology to Aid in GeneSight® Precision Medicine Test AUSTIN, Texas, March, 12, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that its xTAG® Technology has been selected for use in enhancing the processing speed and capacity of Assurex Health's patented GeneSight® tests.  Healthcare providers use GeneSight to help patients affected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar dis... 
Printer Friendly Version
02/17/15Luminex Corporation To Present At Cowen And Company 35th Annual Health Care Conference
AUSTIN, Texas, Feb. 17, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Cowen and Company 35th Annual Health Care Conference to be held March 2-4, 2015, in Boston, MA. The investor presentation will begin at 2:50 p.m. Eastern time on Monday, March 2, 2015.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address ... 
Printer Friendly Version
02/02/15Luminex Corporation Reports Fourth Quarter And Full Year 2014 Results
AUSTIN, Texas, Feb. 2, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the fourth quarter and year ended December 31, 2014.  Financial and operating highlights include the following: Consolidated fourth quarter revenue of $58.1 million, a 5 percent increase compared to the fourth quarter of 2013; full-year 2014 revenue was $227.0 million, a 6 percent increase over 2013. Consolidated gross profit margin was 74 percent for the fourth ... 
Printer Friendly Version
01/28/15Luminex Corporation To Present At 2015 Leerink Global Healthcare Conference
AUSTIN, Texas, Jan. 28, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12, 2015, in New York, NY. The investor presentation will begin at 8:55 a.m. Eastern time on Thursday, February 12, 2015.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the a... 
Printer Friendly Version
01/28/15Luminex Corporation Receives Health Canada Approval for its Comprehensive Genotyping Assay, xTAG® CYP2D6 Kit v3
AUSTIN, Texas, Jan. 28, 2015 /CNW/ -- Luminex Corporation (NASDAQ: LMNX) announced it has received a Health Canada Class 3 Device License approval for its comprehensive genotyping assay, xTAG® CYP2D6 Kit v3. Identification of patient CYP2D6 genotypes can help clinicians individualize drug treatment by selecting appropriate therapies. Cytochrome P450 2D6 (CYP2D6) is a clinically important gene that encodes a drug-metabolizing enzyme. CYP2D6 metabolizes greater than 25% of ... 
Printer Friendly Version
01/21/15Luminex xMAP® Tracks 6 of the Most Dangerous Biotoxins
AUSTIN, Texas, Jan. 21, 2015 /PRNewswire/ -- Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP® Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.1 The ability to simultaneously test for a panel of markers increases ... 
Printer Friendly Version
01/20/15Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 2, 2015
AUSTIN, Texas, Jan. 20, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the fourth quarter and full year ended December 31, 2014 on Monday, February 2, 2015. A press release announcing the results is scheduled for release after the close of trading. Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and twelve months ended December 31, 2014 on February 2, ... 
Printer Friendly Version